MX2022007220A - Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina. - Google Patents

Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.

Info

Publication number
MX2022007220A
MX2022007220A MX2022007220A MX2022007220A MX2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A MX 2022007220 A MX2022007220 A MX 2022007220A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
antitrypsin deficiency
antitrypsin
deficiency
Prior art date
Application number
MX2022007220A
Other languages
English (en)
Inventor
James Andrew Huntington
Nigel Ramsden
David John Fox
James Michael Tomlinson
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of MX2022007220A publication Critical patent/MX2022007220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de oxazol especificados de fórmula (1) y a composiciones farmacéuticas que contienen los compuestos. Los compuestos pueden ser inductores de ¿1-antitripsina (A1AT) y se pueden utilizar en el tratamiento contra una enfermedad o trastorno tal como la deficiencia de ¿1-antitripsina (A1AD o AATD).
MX2022007220A 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina. MX2022007220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918416.7A GB201918416D0 (en) 2019-12-13 2019-12-13 Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
PCT/GB2020/053196 WO2021116710A1 (en) 2019-12-13 2020-12-11 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
MX2022007220A true MX2022007220A (es) 2022-09-07

Family

ID=69186871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007220A MX2022007220A (es) 2019-12-13 2020-12-11 Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.

Country Status (12)

Country Link
US (1) US20230093755A1 (es)
EP (1) EP4073068B1 (es)
JP (1) JP2023506201A (es)
KR (1) KR20220127825A (es)
CN (1) CN115003669A (es)
AU (1) AU2020400334A1 (es)
BR (1) BR112022011564A2 (es)
CA (1) CA3164304A1 (es)
GB (1) GB201918416D0 (es)
IL (1) IL293833A (es)
MX (1) MX2022007220A (es)
WO (1) WO2021116710A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
EP3810131A1 (en) 2018-06-22 2021-04-28 UCL Business Ltd Novel compounds
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina

Also Published As

Publication number Publication date
EP4073068B1 (en) 2024-04-24
WO2021116710A1 (en) 2021-06-17
AU2020400334A1 (en) 2022-07-28
JP2023506201A (ja) 2023-02-15
EP4073068A1 (en) 2022-10-19
KR20220127825A (ko) 2022-09-20
IL293833A (en) 2022-08-01
BR112022011564A2 (pt) 2022-08-30
US20230093755A1 (en) 2023-03-23
CA3164304A1 (en) 2021-06-17
CN115003669A (zh) 2022-09-02
GB201918416D0 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
MX2021004431A (es) Procesos novedosos.
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX2023009856A (es) Dosificacion optimizada de diaminofenotiazinas en poblaciones.
MX2022007219A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
EA202090276A1 (ru) Фармацевтическая композиция для лечения анемии
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
IT201900021564A1 (it) Composizione nutraceutica o farmaceutica comprendente ferro pirofosfato per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di ferro
MX2022007220A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2019000834A (es) Un derivado de oxazina para usar en la prevencion de la enfermedad de alzheimer en pacientes de riesgo.
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical